[1] VoraA, 2007.Approach to management of atrial fibrillation in the Indian scenario,J Assoc Physicians India 55 30 -2
[2] SardarMR,SaeedW,WertanM,BadriM,SenssT,SutterF, 2014.Incidence of postoperative atrial fibrillation (POAF) after robotic CABG versus traditional CABG and its associated mortality and morbidity,J Am Coll Cardiol 63 60431 -9
[3] SardarMR,GrewayA,DeAngelis M., 2015.Cardiovascular impact of eating disorders in adults: A single center experience and literature review,Heart Views 16 88 -
[4] Saeed, 2013.Stroke prevention in atrial fibrillation: Pharmacologic update,Am Med J 4 143 -9
[5] WolfPA,AbbottRD,KannelWB, 1991.Atrial fibrillation as an independent risk factor for stroke: the Framingham study,Stroke J Cereb Circ 22 983 -8
[6] ShafqatS,KellyPJ,FurieKL, 2004.Holter monitoring in the diagnosis of stroke mechanism,Intern Med J 34 305 -9
[7] SardarMR,BadriM,PrinceCT,SeltzerJ,KoweyPR, 2014.Under representation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines,JAMA Intern Med 174 1868 -70
[8] VostA,WolochowDA,HowellDA, 1964.Incidence of infarcts of the brain in heart diseases,J Pathol Bacteriol 88 463 -70
[9] PetersenP,BoysenG,GodtfredsenJ,AndersenED,AndersenB, 1989.Placebo-controlled, randomised trial of Warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation,The Copenhagen AFASAK study. Lancet 1 175 -9
[10] HartRG,PearceLA,AguilarMI, 2007.Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation,Ann Intern Med 146 857 -67
[11] BungardTJ,GhaliWA,TeoKK,McAlisterFA,TsuyukiRT, 2000.Why do patients with atrial fibrillation not receive warfarin?,Arch Intern Med 160 41 -6
[12] BeythRJ,AntaniMR,CovinskyKE, 1996.Why isn't warfarin prescribed to patients with non-rheumatic atrial fibrillation,J Gen Intern Med 11 721 -8
[13] Anon, 1994.Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials,Arch Intern Med 154 1449 -57
[14] BudnitzDS,LovegroveMC,ShehabN,RichardsCL, 2011.Emergency hospitalizations for adverse drug events in older Americans,N Engl J Med 365 2002 -12
[15] KimMM,MetlayJ,CohenA, 2010.Hospitalization costs associated with warfarin-related bleeding events among older communitydwelling adults,Pharmacoepidemiol Drug Saf 19 731 -6
[16] LafataJE,MartinSA,KaatzS,WardRE, 2000.The costeffectiveness of different management strategies for patients on chronic warfarin therapy,J Gen Intern Med 15 31 -7
[17] WannLS,CurtisAB,EllenbogenKA, 2011.ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines,J Am Coll Cardiol 57 1330 -7
[18] European, 2010.Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC),Eur Heart J 31 2369 -2429
[19] ErikssonBI,QuinlanDJ,WeitzJI, ., -
[20] CairnsJA,ConnollyS,McMurtryS,StephensonM,TalajicM, ., -
[21] AdcockAK,Lee-IannottiJK,AguilarMI, 2012.Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic,Neurologist 18 102 -7
[22] PinkJ,LaneS,PirmohamedM,HughesDA, 2011.Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: Quantitative benefit-harm and economic analyses,BMJ 343 d6333 -
[23] SorensenSV,KansalAR,ConnollyS, 2011.Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective,Thromb Haemost 105 908 -19
[24] DavidsonT,HusbergM,JanzonM,OldgrenJ,LevinLÅ, 2013.Costeffectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden,Eur Heart J 34 177 -83
[25] GoAS,FangMC,UdaltsovaN., 2009.Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study,Circulation 119 1363 -9
[26] PoliD,AntonucciE,ZanazziM., 2012.Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics),Thromb Haemost 107 1100 -6
[27] PistersR,LaneDA,NieuwlaatR,de VosCB,CrijnsHJGM,LipGYH, 2010.A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey,Chest 138 1093 -100
[28] MarinighR,LaneDA,LipGYH, 2011.Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk,J Am Coll Cardiol 57 1339 -48
[29] 2016.Commissioner of the Safety Information - Pradaxa (dabigatran etexilate mesylate) capsules,Accessed March 30 -
[30] MackDR,KimJJ, 2012.Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in non-valvular atrial fibrillation,Ann Pharmacother 46 1105 -10
[31] CrowtherMA,WarkentinTE, 2009.Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents,J Thromb Haemost JTH 7 107 -10
[32] PragstI,ZeitlerSH,DoerrB, 2012.Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model,J Thromb Haemost JTH 10 1841 -8
[33] ZhouW,SchwartingS,IllanesS., 2011.Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran,Stroke J Cereb Circ 42 3594 -9
[34] LambourneMD,Eltringham-SmithLJ,GataianceS,ArnoldDM,CrowtherMA,SheffieldWP, 2012.Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate,J Thromb Haemost JTH 10 1830 -40
[35] MarluR,HodajE, 2012.Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: A randomised crossover ex vivo study in healthy volunteers,Thromb Haemost 108 217 -24
[36] WarkentinTE,MargettsP,ConnollySJ,LamyA,RicciC,EikelboomJW, 2012.Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding,Blood 119 2172 -4
[37] GodierA,MiclotA,Le BonniecB, 2012.Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model,Anesthesiology 116 94 -102
[38] EscolarG,Fernandez-GallegoV,Arellano-RodrigoE, 2013.Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: Significance of studies in vitro with circulating human blood,PloS One 8 e78696 -
[39] AnsellJE,BakhruSH,LaulichtBE, 2014.Use of PER977 to reverse the anticoagulant effect of edoxaban,N Engl J Med 371 2141 -2
[40] PollackCV,ReillyPA,EikelboomJ, 2015.Idarucizumab for dabigatran reversal,N Engl J Med 373 511 -20
[41] SchneeweissS,GagneJJ,PatrickAR,ChoudhryNK,AvornJ, 2012.Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation,Circ Cardiovasc Qual Outcomes 5 480 -6
[42] TestaL,AgnifiliM,LatiniRA, 2012.Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation,QJM Mon J Assoc Physicians 105 949 -57
[43] ManthaS,AnsellJ., 2012.An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation,Thromb. Haemost 108 476 -84
[44] SongF,XiongT,Parekh-Bhurke S, 2011.Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study,BMJ 343 d4909 -
[45] BanerjeeA,LaneDA,Torp-PedersenC,LipGYH, 2012.Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a “real world” atrial fibrillation population: A modelling analysis based on a nationwide cohort study,Thromb Haemost 107 584 -9